Company spun out of UMB School of Pharmacy aims to leverage its approach — combining modern artificial intelligence (AI) with traditional mechanistic models — to arm health care professionals with the best data to provide personalized treatment trajectories for patients.

Team of second-year student pharmacists awarded first place in contest that aims to promote student interest in the field of regulatory science.

Application available to download for Android and iOS offers guidance to health care professionals in selecting and dosing anticoagulant therapy for patients.

Independent group will evaluate costs for certain new and existing medications and make recommendations about how to curb high drug prices.

Day-long event provides glimpses into potential careers for students and allows alumni to reconnect with faculty and one another.

Established with a $750,000 gift from the Gyi Family, the Felix A. Khin-Maung-Gyi Memorial Scholarship for Pharmapreneurship provides one full year of tuition for a student pharmacist who has demonstrated a commitment to entrepreneurship.

Leaders in technology and pharmacy collaborate to offer the first technology-enabled adherence solution to fight the country’s deadliest chronic diseases.

Students enrolled in online program travel from around the world for opportunity to interact with each other in-person and network with leaders in the medical cannabis industry.

Research team led by Dr. Linda Wastila aims to understand how a nationwide effort to reduce the use of antipsychotic medications in long-term care facilities has impacted those facilities’ use of other medications and patient health outcomes.

New company established by School of Pharmacy faculty members releases its first software platform designed to assist strategic decision making across the fields of drug development and individualized patient care.

Publication offers guidance for hospice and palliative care practitioners that aims to maximize benefits and minimize risks of methadone therapy in patients with serious illness.

Two-year program is the first of its kind in the U.S. to provide students with the knowledge needed to support patients and the medical cannabis industry, add to existing research, and develop well-informed medical cannabis policy.